Zingue Stéphane, Fotsing Fongang Yannick Stéphane, Ossomba Eric Roger, Tatsinda Vanneck, Silihe Kevine Kamga, Mbou William Defo, Fogang Balotin, Essomba René, Chouna Jean Rodolphe, Njamen Dieudonné, Ayong Lawrence
Department of Pharmacotoxicology and Pharmacokinetics, Faculty of Medicine and Biomedical Sciences, University of Yaounde, 1, P.O. Box 1364, Yaounde, Cameroon.
Department of Chemistry, Higher Teachers' Training College, University of Maroua, P.O. Box 55, Maroua, Cameroon.
Heliyon. 2024 Jul 23;10(15):e35000. doi: 10.1016/j.heliyon.2024.e35000. eCollection 2024 Aug 15.
Recent developments in cancer research indicate that cancer is a manifestation of immune system dysfunction. Many natural anticancer agents developed recently possess immune-modulatory properties. In our ongoing pursuit of anticancer alternatives, we evaluated the immune-modulatory potential of oligandrin, an ent-pimarane type diterpenoid from .
we assessed on Breast cancer patients' peripheral blood mononuclear cells (PBMCs) were isolated to assess the effect of oligandrin (0.5, 1, 10, 100, 200 mg/mL) using the Ficoll-histopaque density centrifugation method. The parameters that were assessed included, PBMC viability and cytokine (IL-6, IL-12, IL-10, EGF, TNF-α, INF-γ) production. , we chemically induced breast cancer using DMBA (50 mg/kg BW) in Wistar rats, then treated them with oligandrin (1 mg/kg BW) or standards (tamoxifen 3.3 mg/kg; letrozole 1 mg/kg) for 20 weeks. The parameters that were evaluated included, tumor burden, volume, incidence, histopathology, antioxidant, and inflammatory status.
Oligandrin (1, 10, 100 and 200 μg/mL) significantly increased ( < 0.05) PBMC cell number 24 h after incubation. , it induced 62.5 % tumor incidence reduction compared to DMBA rats (100 %). Oligandrin significantly protected ( < 0.001) rats against increased tumor burden, mass and volume, which was accompanied by a significant antioxidant effect [increment of GSH ( < 0.01) and SOD ( < 0.001)]. Oligandrin prevented high-grade adenocarcinomas according to SBR stratification and significantly reduced pro-inflammatory cytokine levels (IL-6, IL-12) while increasing anti-inflammatory cytokine levels (INF-γ).
Oligandrin is reported for the first time to protect against breast cancer onset and this effect seems to be at least in part attributable to its immune-boosting capacity.
癌症研究的最新进展表明，癌症是免疫系统功能障碍的一种表现。最近开发的许多天然抗癌剂都具有免疫调节特性。在我们对抗癌替代品的持续探索中，我们评估了橄榄树脂素（一种来自[具体来源未给出]的对映-海松烷型二萜）的免疫调节潜力。
我们对乳腺癌患者的外周血单个核细胞（PBMC）进行分离，采用Ficoll-泛影葡胺密度离心法评估橄榄树脂素（0.5、1、10、100、200mg/mL）的作用。评估的参数包括PBMC活力和细胞因子（IL-6、IL-12、IL-10、EGF、TNF-α、INF-γ）产生。此外，我们用二甲基苯并蒽（DMBA，50mg/kg体重）在Wistar大鼠中化学诱导乳腺癌，然后用橄榄树脂素（1mg/kg体重）或标准药物（他莫昔芬3.3mg/kg；来曲唑1mg/kg）治疗20周。评估的参数包括肿瘤负荷、体积、发病率、组织病理学、抗氧化和炎症状态。
孵育24小时后，橄榄树脂素（1、10、100和200μg/mL）显著增加（P<0.05）PBMC细胞数量。此外，与DMBA诱导的大鼠（100%）相比，它使肿瘤发病率降低了62.5%。橄榄树脂素显著保护（P<0.001）大鼠免受肿瘤负荷、肿块和体积增加的影响，同时伴有显著的抗氧化作用[谷胱甘肽（GSH）增加（P<0.01）和超氧化物歧化酶（SOD）增加（P<0.001）]。根据SBR分级，橄榄树脂素可预防高级别腺癌，并显著降低促炎细胞因子水平（IL-6、IL-12），同时增加抗炎细胞因子水平（INF-γ）。
首次报道橄榄树脂素可预防乳腺癌发病，且这种作用似乎至少部分归因于其免疫增强能力。
